AV 0328

Drug Profile

AV 0328

Alternative Names: AV0328

Latest Information Update: 30 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alopexx Vaccine
  • Class Oligosaccharides; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Bacterial infections
  • Preclinical Staphylococcal infections

Most Recent Events

  • 25 Oct 2017 Immunogenicity and antimicrobial data from the phase I/II trial in Healthy volunteers released by Alopexx Vaccine
  • 25 Oct 2017 Alopexx Vaccine completes a phase I/II trial in Bacterial infections (In volunteers) in USA (IM) (NCT02853617)
  • 25 Oct 2017 Alopexx Vaccine plans a phase II trial for Bacterial infections in first quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top